On the one hand, unraveling the mechanisms that allow VNPs to maintain the CD4+ T cell homeostasis could benefit immune non-responders, who represent 10%–40% of all ART-treated people,1 do not recover normal CD4+ T cell counts despite suppressed viremia, and suffer an increased risk of morbidity and mortality from AIDS and non-AIDS events. This evidence concerns the gene CD4 and AIDS.